30,153 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by SEB Asset Management AB

SEB Asset Management AB purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 1st quarter, Holdings Channel reports. The fund purchased 30,153 shares of the biopharmaceutical company’s stock, valued at approximately $9,977,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Norges Bank bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $895,816,000. Qube Research & Technologies Ltd bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $369,943,000. AQR Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 295.2% during the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock worth $336,009,000 after buying an additional 555,759 shares in the last quarter. Orbis Allan Gray Ltd increased its stake in shares of Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after buying an additional 486,489 shares during the period. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2,221.7% during the third quarter. Jacobs Levy Equity Management Inc. now owns 410,342 shares of the biopharmaceutical company’s stock valued at $187,116,000 after buying an additional 392,668 shares during the period. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on ALNY. Truist Financial reduced their price target on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a report on Monday, July 13th. Chardan Capital reiterated a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Citigroup started coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They set a “buy” rating and a $380.00 price objective on the stock. Royal Bank Of Canada reduced their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Finally, Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $455.31.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $272.67 on Tuesday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $266.27 and a twelve month high of $495.55. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The company has a market cap of $36.40 billion, a PE ratio of 74.50 and a beta of 0.27. The company’s 50 day moving average is $293.92 and its 200 day moving average is $319.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business’s quarterly revenue was up 96.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.44) EPS. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.26 EPS for the current year.

Insider Activity

In related news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.